CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

In vitro contract research services

Make more informed decisions through our In Vitro Contract Research Services


We offer standard and bespoke in vitro studies as a service to screen your novel therapeutic candidates, investigate mechanisms of action and fast-track clinical trial design. Our services are ideal for drug developers who need quick access to organ-on-a-chip (OOC) technology without the need to invest in equipment.

Partner with us to access over a decade of OOC expertise, the most human-relevant in vitro models available, our dedicated team of creative problem solvers, and a proven track record for delivering clinically translatable results.

Your dedicated contact will work with you to design and conduct studies that get results quickly and cost-effectively compared to animal studies. All studies are performed using PhysioMimix™ technology to generate human-relevant data that improves your chances of clinical success.

Explore our services

arrow down |
CN Bio Contract Research Services team photo
NAFLD / NASH Services

NAFLD / NASH Services

Overcome the limitations of murine models through our complementary service to understand the human efficacy of novel anti-NASH therapeutics. Gain mechanistic insights from a range of disease markers (hepatic steatosis, inflammation, fibrosis) and target pathways.

Learn more
Drug-induced liver injury Services

Drug-induced liver injury Services

Our DILI Services offer a reliable tool for evaluating drug safety in a human-relevant system. We can evaluate multiple endpoints to establish a complete assessment of acute or chronic DILI risk using a wide range of clinically relevant endpoints to determine causality and mechanism of toxicity.

Learn more
ADME Services

ADME Services

Take a step beyond what’s currently possible to gain deeper insights into the ADME properties of a wide variety of drug modalities. Identify and correlate human-specific metabolites with cell health or more accurately predict bioavailability versus animals to select candidates with desirable profiles.

Learn more
Oncology Services

Oncology Services

Use Oncology Services to guide clinical study design for the rapid development of new therapeutics without xenografts. Perform unique studies using an in vitro microfluidic platform that replicates in vivo PK profiles to explore human PK/PD relationships, in vivo or in silico findings, drug dosing regimens, and combinations.

Learn more

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023